Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2024 · 10-Q
Revenue$128.23M$128.23M+2,399.6% vs Q2 2023 Net Income$69.52M$69.52MN/M vs Q2 2023 EPS Diluted$0.04$0.04N/M vs Q2 2023 Operating Income$68,700,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$46,977,000N/M Margins · derivedOperating margin53.6%+929.0 pt vs Q2 2023
Net margin54.2%+471.2 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 12, 2024 · 43 d after period end